Shuxing Zhang, PhD
Full Member, Cancer Biology Program, University of Hawaiʻi Cancer Center
Academic Appointment(s):
Professor (Researcher), University of Hawaiʻi Cancer Center
Degree(s):
Ph.D, School of Pharmacy, The University of North Carolina at Chapel Hill
Honor(s) and Award(s)
2001 – Impact Award, Becton Dickinson Technologies
2004 – CCG Excellence Awards, American Chemical Society
2008 – Hewlett Packard Outstanding Scholar Awards, American Chemical Society
2013 – Travel Award, Pacific Symposium on Biocomputing
2014 – Provost Wall of Science Award, MD Anderson Cancer Center
2015 – Faculty Scholars Award, MD Anderson Cancer Center
2018 – Potu Rao Excellence Awards of Basic Science, MD Anderson Cancer Center
2020 – President’s Recognition of Faculty Excellence Awards in Education, MD Anderson Cancer Center
2021 – Wall of Science Award, MD Anderson Cancer Center
Research Focus
In the Intelligent Molecular Discovery Laboratory (iMDL), we are dedicated to development of novel computational and artificial intelligence (AI) approaches and their application to rational cancer drug design and discovery. Particularly, we are interested in combining data science such as big multi-omics data curation and state-of-the-art AI techniques including large language models (LLM), along with high-throughput and high-content screening (HTC/HCS) technologies, to develop more efficacious but less toxic drugs for personalized cancer treatment. In addition, we implement cutting-edge virtual reality (VR) and augmented reality (AR) technologies to transform our research and education. As an interdisciplinary laboratory, we have been collaborating with experts across the globe in chemistry, biology, pharmacology, and clinical trials to translate our laboratory discoveries to bedside applications and saved many patients’ lives. We have been issued with more than 15 US/international patents, and our trainee-driven projects have advanced to different stages of preclinical and clinical trials. For more information, please visit https://imdlab.net.
Selected Publications
Fong LWR, Lee J, Lin HK, Ueno NT, Zhang S*. A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. Sci Rep. 2022 Feb 15;12(1):2478.
Li Y, Tan Z, Zhang Y, Zhang Z, Hu Q, Liang K, Jun Y, Ye Y, Li YC, Li C, Liao L, Xu J, Xing Z, Pan Y, Chatterjee SS, Nguyen TK, Hsiao H, Egranov SD, Putluri N, Coarfa C, Hawke DH, Gunaratne PH, Tsai KL, Han L, Hung MC, Calin GA, Namour F, Guéant JL, Muntau AC, Blau N, Sutton VR, Schiff M, Feillet F*, Zhang S*, Lin C*, Yang L*. A noncoding RNA modulator potentiates phenylalanine metabolism in mice. Science. 2021 Aug 6;373(6555):662-673. PMID: 34353949.
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR/HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018. May;24(5):638-646. PMCID: PMC5964608.
Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S*, Lin HK*. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression. Cell, 2013, 154(3):556-68. PMCID: PMC3845452.
Chen L, Moses SA, Du-Cuny L, Mathew S, Dumas S, Song Z, Meuillet EJ, Zhang S*. Identification and evaluation of potent small molecule inhibitors targeting GAB1 pleckstrin homology domain. PLoS Comput. Biol. 2015 Jan 8;11(1):e1004021. PMCID: PMC4287437.
Publication list via NIH MyBibliography
Publication list via Google Scholar
Active Grants
Shuxing Zhang, PI
University of Hawaiʻi Cancer Center
Startup
AI and Experimental Cancer Therapeutics Discovery and Development
07/2024 – 06/2027
Shuxing Zhang, Co-I (PI: Bast)
NIH
1R01CA266187-01A1
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition
09/01/2023 – 8/31/2028
Shuxing Zhang, Co-I (PI: DePinho)
DOD
W81XWH-20-PCRP-IDA
Identification of collateral lethal targets in prostate cancer
10/01/2021 – 09/30/2024
